Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome - Slideshow (NASDAQ:ARWR) 2025-11-19
Arrowhead Pharmaceuticals(US:ARWR) Seeking Alpha·2025-11-19 07:49Group 1 - The article does not provide any relevant content regarding company or industry insights [1]